Journal of Clinical Oncology, Vol 18, Issue 1
(January), 2000: 122
© 2000 American Society for Clinical Oncology
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
By A. B. Sandler,
J. Nemunaitis,
C. Denham,
J. von Pawel,
Y. Cormier,
U. Gatzemeier,
K. Mattson,
Ch. Manegold,
M. C. Palmer,
A. Gregor,
B. Nguyen,
C. Niyikiza,
L. H. Einhorn
From the Hoosier Oncology Group, The Walther Cancer Institute, and the Department of Medicine, Indiana University, Indianapolis; and Eli Lilly and Company, Indianapolis, IN; Physicians Reliance Network, Dallas, TX; Zentralkrankenhaus, Gauting; Grosshansdorf Hospital, Hamburg; and Thoraxklinik, Heidelberg, Germany; Centre de Pneumonologie de Laval, Quebec; and Cross Cancer Institute, Alberta, Canada; Helsinki University Hospital, Helsinki, Finland; and Western General Hospital, Edinburgh, Scotland.
Address reprint requests to Alan Sandler, MD, Indiana University Indiana Cancer Pavilion, Room 473 535 Barnhill Dr, Indianapolis, IN 46202-5286; email asandler{at}iupuie.edu
PURPOSE: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non–small-cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC.
PATIENTS AND METHODS: Patients were randomized to receive either cisplatin (100 mg/m2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m2 intravenously on day 1) plus gemcitabine (1,000 mg/m2 administered intravenously on days 1, 8, and 15 of a 28-day cycle).
RESULTS: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25.4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004).
CONCLUSIONS: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.
Presented in part at the 34st Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Hiramatsu, Y. Iwasaki, Y. Koyama, N. Tamiya, S. Hosogi, M. Nakanishi, Y. Kohno, M. Ueda, T. Arimoto, and Y. Marunaka
Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer
Jpn. J. Clin. Oncol.,
December 1, 2009;
39(12):
779 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Mom, J. Verweij, C. N.A.M. Oldenhuis, J. A. Gietema, N. L. Fox, R. Miceli, F. A.L.M. Eskens, W. J. Loos, E. G.E. de Vries, and S. Sleijfer
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Clin. Cancer Res.,
September 1, 2009;
15(17):
5584 - 5590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cohen, R. Justice, and R. Pazdur
Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
Oncologist,
September 1, 2009;
14(9):
930 - 935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kanai, S. Morita, S. Matsumoto, T. Nishimura, E. Hatano, S. Yazumi, T. Sasaki, H. Yasuda, T. Kitano, A. Misawa, et al.
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia
Ann. Onc.,
August 1, 2009;
20(8):
1397 - 1401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ceresa, E. Giovannetti, J. Voortman, A. C. Laan, R. Honeywell, G. Giaccone, and G. J. Peters
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1026 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist,
May 1, 2009;
14(5):
497 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan
Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
Ann. Pharmacother.,
November 1, 2008;
42(11):
1640 - 1652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Einhorn
First-Line Chemotherapy for Non-Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?
J. Clin. Oncol.,
July 20, 2008;
26(21):
3485 - 3486.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata, Y. Ichinose, M. Tsuboi, S. Yokota, K. Nakagawa, M. Suga, et al.
Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
Am. J. Respir. Crit. Care Med.,
June 15, 2008;
177(12):
1348 - 1357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Edelman, D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al.
Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203
J. Clin. Oncol.,
February 20, 2008;
26(6):
848 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ramalingam and C. Belani
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Oncologist,
January 1, 2008;
13(suppl_1):
5 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang
Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts
Clin. Cancer Res.,
December 1, 2007;
13(23):
7166 - 7171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ali, Y. Lin, M. M. Gharibo, M. K. Gounder, M. N. Stein, T. F. Lagattuta, M. J. Egorin, E. H. Rubin, and E. A. Poplin
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Clin. Cancer Res.,
October 1, 2007;
13(19):
5876 - 5882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ueno, T. Okusaka, M. Ikeda, C. Morizane, T. Ogura, A. Hagihara, and T. Tanaka
Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer
Jpn. J. Clin. Oncol.,
August 2, 2007;
(2007)
hym060v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Voortman, E. F. Smit, R. Honeywell, B. C. Kuenen, G. J. Peters, H. van de Velde, and G. Giaccone
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Clin. Cancer Res.,
June 15, 2007;
13(12):
3642 - 3651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tooker, W.-C. Yen, S.-C. Ng, A. Negro-Vilar, and T. W. Hermann
Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification
Cancer Res.,
May 1, 2007;
67(9):
4425 - 4433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, H. Karnicka-Mlodkowski, M. Pesek, P. Serwatowski, et al.
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
J. Clin. Oncol.,
April 20, 2007;
25(12):
1545 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
N. Engl. J. Med.,
February 22, 2007;
356(8):
800 - 808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res.,
January 15, 2007;
13(2):
515 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. N. Chhajed, F. Baty, M. Pless, S. Somandin, M. Tamm, and M. H. Brutsche
Outcome of Treated Advanced Non-small Cell Lung Cancer With and Without Central Airway Obstruction
Chest,
December 1, 2006;
130(6):
1803 - 1807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Auperin, C. Le Pechoux, J. P. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. G. Trovo, H. J. M. Groen, et al.
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
Ann. Onc.,
March 1, 2006;
17(3):
473 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-L. Lai, C.-M. Tsai, C.-H. Chiu, G.-S. Wang, W.-J. Su, Y.-M. Chen, and R.-P. Perng
Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol.,
December 1, 2005;
35(12):
700 - 706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. van Meerbeeck, R. Gaafar, C. Manegold, R. J. Van Klaveren, E. A. Van Marck, M. Vincent, C. Legrand, A. Bottomley, C. Debruyne, and G. Giaccone
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
J. Clin. Oncol.,
October 1, 2005;
23(28):
6881 - 6889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
September 1, 2005;
23(25):
5929 - 5937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Edelman, R. Smith, P. Hausner, L. A. Doyle, K. Kalra, J. Kendall, M. Bedor, and S. Bisaccia
Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
August 20, 2005;
23(24):
5774 - 5778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Bunn Jr
Platinums in Lung Cancer: Sufficient or Necessary?
J. Clin. Oncol.,
May 1, 2005;
23(13):
2882 - 2883.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Matsui, T. Hirashima, T. Nitta, M. Kobayashi, Y. Ogata, M. Furukawa, S. Kudoh, N. Yoshimura, T. Mukohara, S. Yamauchi, et al.
A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol.,
April 1, 2005;
35(4):
181 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Pujol, J.-L. Breton, R. Gervais, P. Rebattu, A. Depierre, J.-F. Morere, B. Milleron, D. Debieuvre, D. Castera, P.-J. Souquet, et al.
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
Ann. Onc.,
April 1, 2005;
16(4):
602 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless
Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade
Chest,
March 1, 2005;
127(3):
738 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.M. Rudd, N.H. Gower, S.G. Spiro, T.G. Eisen, P.G. Harper, J.A.H. Littler, M. Hatton, P.W.M. Johnson, W.M.C. Martin, E.M. Rankin, et al.
Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group
J. Clin. Oncol.,
January 1, 2005;
23(1):
142 - 153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. Douillard, R. Gervais, G. Dabouis, A. Le Groumellec, M. D'Arlhac, D. Spaeth, B. Coudert, D. Caillaud, A. Monnier, C. Clary, et al.
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
Ann. Onc.,
January 1, 2005;
16(1):
81 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Edelman, J. I. Clark, K. Chansky, K. Albain, N. Bhoopalam, G. R. Weiss, J. K. Giguere, K. Kelly, J. Crowley, and D. R. Gandara
Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel
Clin. Cancer Res.,
August 1, 2004;
10(15):
5022 - 5026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
JAMA,
July 28, 2004;
292(4):
470 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bepler, S. Sharma, A. Cantor, A. Gautam, E. Haura, G. Simon, A. Sharma, E. Sommers, and L. Robinson
RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 15, 2004;
22(10):
1878 - 1885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Iop, A. M. Manfredi, and S. Bonura
Fatigue in cancer patients receiving chemotherapy: an analysis of published studies
Ann. Onc.,
May 1, 2004;
15(5):
712 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Giaccone, J. L. Gonzalez-Larriba, A. T. van Oosterom, R. Alfonso, E. F. Smit, M. Martens, G. J. Peters, W. J. F. van der Vijgh, R. Smith, S. Averbuch, et al.
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
Ann. Onc.,
May 1, 2004;
15(5):
831 - 838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
Ann. Onc.,
March 1, 2004;
15(3):
410 - 418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. De Lange, C. J. van Groeningen, J. R. Kroep, A. Van Bochove, J. F. Snijders, G. J. Peters, H. M. Pinedo, and G. Giaccone
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer
Ann. Onc.,
March 1, 2004;
15(3):
484 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Giaccone, R. S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R. B. Natale, J. H. Schiller, J. von Pawel, A. Pluzanska, et al.
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 1
J. Clin. Oncol.,
March 1, 2004;
22(5):
777 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Spira and D. S. Ettinger
Multidisciplinary Management of Lung Cancer
N. Engl. J. Med.,
January 22, 2004;
350(4):
379 - 392.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol.,
January 15, 2004;
22(2):
330 - 353.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, N. Katakami, T. Sugiura, M. Kawahara, A. Yokoyama, S. Yokota, et al.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group
J. Clin. Oncol.,
January 15, 2004;
22(2):
254 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Gatzemeier, G. Groth, C. Butts, N. Van Zandwijk, F. Shepherd, A. Ardizzoni, C. Barton, P. Ghahramani, and V. Hirsh
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ann. Onc.,
January 1, 2004;
15(1):
19 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al.
Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
J. Clin. Oncol.,
November 1, 2003;
21(21):
3909 - 3917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, L. A. Hammond, D. P. Carbone, H. T. Tran, K. J. Holroyd, A. Desai, J. I. Williams, B. N. Bekele, H. Hait, V. Allgood, et al.
A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
September 15, 2003;
9(11):
4108 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell, C. Vadell, I. Bover, A. Ruiz-Casado, P. Azagra, U. Jimenez, et al.
Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
J. Clin. Oncol.,
September 1, 2003;
21(17):
3207 - 3213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crul, N. E. Schoemaker, D. Pluim, M. Maliepaard, R. W. M. Underberg, M. Schot, R. W. Sparidans, P. Baas, J. H. Beijnen, N. van Zandwijk, et al.
Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
September 1, 2003;
9(10):
3526 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bottomley, F. Efficace, R. Thomas, V. Vanvoorden, and S. H. Ahmedzai
Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials
J. Clin. Oncol.,
August 1, 2003;
21(15):
2982 - 2992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach
Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
Oncologist,
June 1, 2003;
8(3):
270 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Mauer, R. H. Ansari, P. C. Hoffman, S. A. Krauss, D. Taber, S. A. Tembe, G. T. Gabrys, T. Cotter, L. P. Schumm, L. Szeto, et al.
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer
Ann. Onc.,
May 1, 2003;
14(5):
722 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Kosmidis
In Reply:
J. Clin. Oncol.,
February 15, 2003;
21(4):
756 - 756.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nagai, R. Tsuchiya, T. Mori, H. Tada, Y. Ichinose, T. Koike, and H. Kato
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)
J. Thorac. Cardiovasc. Surg.,
February 1, 2003;
125(2):
254 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bajetta, S. C. Stani, D. De Candis, N. Zaffaroni, N. Zilembo, D. Cortinovis, S. Aglione, L. Mariani, B. Formisano, and P. Bidoli
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer
Ann. Onc.,
February 1, 2003;
14(2):
242 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer
Chest,
January 1, 2003;
123
(2009):
226S - 243S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med.,
November 1, 2002;
166(9):
1166 - 1196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, et al.
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
November 1, 2002;
20(21):
4285 - 4291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
J. Clin. Oncol.,
October 15, 2002;
20(20):
4191 - 4198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Bunn Jr
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?
J. Clin. Oncol.,
September 15, 2002;
20(90001):
23s - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nottage and L. L. Siu
Principles of Clinical Trial Design
J. Clin. Oncol.,
September 15, 2002;
20(90001):
42s - 46.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Bunn Jr
Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations
J. Clin. Oncol.,
September 1, 2002;
20(17):
3565 - 3567.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faivre, T. Le Chevalier, C. Monnerat, F. Lokiec, S. Novello, J. Taieb, P. Pautier, C. Lhomme, P. Ruffie, L. Kayitalire, et al.
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
Ann. Onc.,
September 1, 2002;
13(9):
1479 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Soto Parra, R. Cavina, F. Latteri, A. Sala, M. Dambrosio, G. Antonelli, E. Morenghi, M. Alloisio, G. Ravasi, and A. Santoro
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Ann. Onc.,
July 1, 2002;
13(7):
1080 - 1086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, J. R. Gray, L. H. Morrissey, L. A. Kalman, J. K. Hon, and F. A. Greco
Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
July 1, 2002;
20(13):
2937 - 2942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. N. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sanchez, P. H. Gumerlock, M. Taron, et al.
Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
July 1, 2002;
8(7):
2286 - 2291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Ettinger
Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer?
Oncologist,
June 1, 2002;
7(3):
226 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. George, N. J. Vogelzang, B. I. Rini, F. J. Geoffroy, P. Kollipara, and W. M. Stadler
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma
Ann. Onc.,
January 19, 2002;
13(1):
116 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-M. Chen, R.-P. Perng, Y.-C. Lee, J.-F. Shih, C.-S. Lee, C.-M. Tsai, and J. Whang-Peng
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated
Ann. Onc.,
January 1, 2002;
13(1):
108 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
Thorax,
January 1, 2002;
57(1):
20 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al.
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
December 1, 2001;
7(12):
3942 - 3949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Inoue and N. Saijo
Recent Advances in the Chemotherapy of Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol.,
July 1, 2001;
31(7):
299 - 304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kelly, J. Crowley, P. A. Bunn Jr, C. A. Presant, P. K. Grevstad, C. M. Moinpour, S. D. Ramsey, A. J. Wozniak, G. R. Weiss, D. F. Moore, et al.
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial
J. Clin. Oncol.,
July 1, 2001;
19(13):
3210 - 3218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Khuri, J. R. Rigas, R. A. Figlin, R. J. Gralla, D. M. Shin, R. Munden, N. Fox, M. R. Huyghe, Y. Kean, S. D. Reich, et al.
Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 15, 2001;
19(10):
2626 - 2637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. S. Breathnach, B. Freidlin, B. Conley, M. R. Green, D. H. Johnson, D. R. Gandara, M. O'Connell, F. A. Shepherd, and B. E. Johnson
Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results
J. Clin. Oncol.,
March 15, 2001;
19(6):
1734 - 1742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Isla, R. Rosell, J. J. Sanchez, A. Carrato, E. Felip, C. Camps, A. Artal, J. L. Gonzalez-Larriba, P. Azagra, V. Alberola, et al.
Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
February 15, 2001;
19(4):
1071 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale
Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
February 15, 2001;
19(4):
1078 - 1087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al.
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
October 19, 2000;
18(19):
3390 - 3399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, and P. A. Bunn Jr.
A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
September 1, 2000;
6(9):
3474 - 3479.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. J. Lynch Jr.
Lung Cancer Highlights
Oncologist,
August 1, 2000;
5(4):
274 - 279.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. L. R. Mitchell and A. Sandler
Quality of Life and Cisplatin-Gemcitabine Chemotherapy
J. Clin. Oncol.,
July 14, 2000;
18(14):
2791 - 2792.
[Full Text]
[PDF]
|
|
|
|
